Innate Immunotherapeutics (IIL)
Innate Immunotherapeutics Ltd. is a medical biotechnology company. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The same technology can be used in the design of better vaccines to treat or prevent diseases such as influenza, cancer, malaria, or tuberculosis and by using this technology MIS416 was developed. Innate Immunotherapeutics was founded on May 31, 2000 and is headquartered in Sydney, Australia.
|Market Price at 20-11-2017||$0.03|
|Price to Earnings Ratio||-23.29|
|Market Capitalisation||$6.09 (million)|
|Return on Equity (ROE)||-106.79%|